Apixaban- and Rivaroxaban-Associated Bleeding: A Retrospective Analysis Using the FDA Adverse Event Reporting System

Ilana K Logvinsky; Christian Sanchez; Claudiu Ciuciureanu; Eric Wu; Osama El Aryan; Maja Delibasic

Journal ArticleOPEN ACCESS

Apixaban- and Rivaroxaban-Associated Bleeding: A Retrospective Analysis Using the FDA Adverse Event Reporting System

Logvinsky I
Sanchez C
Ciuciureanu C
et al.

Cureus (2025)

DOI: 10.7759/cureus.85509

N/ACitations

5Readers

Abstract

… prevent blood clots and strokes in individuals with atrial fibrillation (AF). We extracted data … AF trial, major GI bleeding was more commonly seen with rivaroxaban than with warfarin [8], …

Cite

CITATION STYLE

APA

Logvinsky, I. K., Sanchez, C., Ciuciureanu, C., Wu, E., El Aryan, O., & Delibasic, M. (2025). Apixaban- and Rivaroxaban-Associated Bleeding: A Retrospective Analysis Using the FDA Adverse Event Reporting System. Cureus. https://doi.org/10.7759/cureus.85509

Apixaban- and Rivaroxaban-Associated Bleeding: A Retrospective Analysis Using the FDA Adverse Event Reporting System

Abstract

Cite

Register to see more suggestions